Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics of naproxen in elderly patients

Pharmacokinetics of naproxen in elderly patients 228 31 31 4 4 R. M. McVerry J. Lethbridge N. Martin S. K. Mukerjee T. Littler R. Tallis R. Sibeon M. L. E. Orme Department of Geriatrics University of Liverpool UK Pharmacology and Therapeutics University of Liverpool UK Regional Rheumatology Unit Arrowe Park Hospital Wirral UK Summary The pharmacokinetics of naproxen have been examined in 13 elderly patients (mean age 84.2 years) and in 9 younger patients (mean age 53.9 years) at the end of a 21 day course of therapy with naproxen 500 mg b.d. The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 µ g · ml −1 ). The AUC (0–24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 µg·ml −1 ·h kg −1 p⩽0.02). The AUC was significantly higher in the elderly group compared to the control group also in the normalized form. The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml·h −1 ). The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng·ml −1 ). Although there was no excess of side effects in the elderly patients it is suggested that when naproxen is given to elderly patients, therapy should be started at the lower end of the dosage range. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Loading next page...
 
/lp/springer-journals/pharmacokinetics-of-naproxen-in-elderly-patients-02KKwVh1JJ

References (21)

Publisher
Springer Journals
Copyright
Copyright © 1986 by Springer-Verlag
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
DOI
10.1007/BF00613525
Publisher site
See Article on Publisher Site

Abstract

228 31 31 4 4 R. M. McVerry J. Lethbridge N. Martin S. K. Mukerjee T. Littler R. Tallis R. Sibeon M. L. E. Orme Department of Geriatrics University of Liverpool UK Pharmacology and Therapeutics University of Liverpool UK Regional Rheumatology Unit Arrowe Park Hospital Wirral UK Summary The pharmacokinetics of naproxen have been examined in 13 elderly patients (mean age 84.2 years) and in 9 younger patients (mean age 53.9 years) at the end of a 21 day course of therapy with naproxen 500 mg b.d. The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 µ g · ml −1 ). The AUC (0–24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 µg·ml −1 ·h kg −1 p⩽0.02). The AUC was significantly higher in the elderly group compared to the control group also in the normalized form. The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml·h −1 ). The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng·ml −1 ). Although there was no excess of side effects in the elderly patients it is suggested that when naproxen is given to elderly patients, therapy should be started at the lower end of the dosage range.

Journal

European Journal of Clinical PharmacologySpringer Journals

Published: Jul 1, 1986

There are no references for this article.